AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential Over $500 Million

According to a recent LinkedIn post from BioSpectator Inc, AstraZeneca has reportedly exercised an option on Pinetree Therapeutics’ EGFR bispecific antibody degrader PTX-299 in under two years. The post cites AstraZeneca’s Q1 earnings disclosure as indicating that the company opted to acquire global exclusivity rights to PTX-299, with potential development, regulatory, and commercialization milestones exceeding $500 million, plus separate sales royalties.

The LinkedIn post highlights that EGFR has traditionally been seen as difficult to target with small-molecule degraders, and that PTX-299 instead uses a bispecific antibody format to drive lysosomal degradation of EGFR. Unlike existing EGFR TKIs such as Tagrisso, which inhibit specific mutations, PTX-299 is described as a pan-EGFR degrader designed to remove EGFR itself regardless of mutation type, suggesting a differentiated mechanism that could expand therapeutic reach in EGFR-driven cancers.

For investors, the reported option exercise and associated milestone structure underscore sustained big-pharma interest and capital allocation into novel EGFR-targeting modalities. If PTX-299 advances successfully through development, the economics referenced in the post imply a potentially meaningful non-dilutive funding and royalty stream for Pinetree Therapeutics, while reinforcing AstraZeneca’s strategy to diversify beyond traditional TKIs in its oncology portfolio.

More broadly, the post suggests growing validation of antibody-based degrader approaches in targets historically viewed as less tractable for small-molecule degradation. This trend may influence valuation and partnering dynamics for other companies pursuing protein degradation platforms, particularly those focused on receptor tyrosine kinases, as large pharma appears willing to commit substantial milestone packages to access differentiated oncology assets.